A common osteoporosis drug blocked spinal damage in a surprising new study

Researchers using zebrafish models have discovered that a common osteoporosis drug can prevent spinal tissue hardening and disc degeneration. This finding suggests that existing medications could be repurposed to treat chronic back pain by addressing the underlying biological causes of spinal deterioration.
Why it matters
Chronic back pain is a major global health issue, and finding an existing drug that can stop or reverse disc degeneration could significantly improve patient outcomes and reduce healthcare costs.
An existing osteoporosis drug has shown surprising promise in protecting the spine from damage, raising hopes for new treatments for chronic neck and back pain. In experiments involving zebrafish, researchers found that the medication prevented abnormal mineral deposits from forming in the spine, a process that can cause spinal tissues to harden and vertebrae to fuse together.
The discovery could help scientists tackle one of the underlying causes of back pain: the gradual deterioration of the discs that cushion the bones of the spine. Researchers also identified changes in gene activity and metabolism that appear to contribute to this damage, revealing several possible targets for future treatments.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in